Insights - Titan Pharmaceuticals’ (TTNP) implantable device for the treatment of opioid addiction performed as well as standard sublingual buprenorphine tablets in a phase 3 study, the … Continue Reading
Read NowInsights - Lets take a quick look at the current state of affairs in biotech & biopharma. We write often about the IBB, which is iShares’ Nasdaq Biotechnology … Continue Reading
Read NowInsights - Bluebird bio (BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red blood cells, … Continue Reading
Read NowInsights - Achillion Pharmaceuticals (ACHN) announced after the close on Tuesday a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, of Johnson & Johnson (JNJ), to develop … Continue Reading
Read NowInsights - Sorrento Therapeutics (SRNE) has sold lead drug candidate Cynviloq to NantPharma, founded by healthcare entrepreneur & SRNE’s largest investor, Patrick Soon-Shiong, and a subsidiary of partner NantWorks. Sorrento … Continue Reading
Read NowInsights - An independent advisory committee to the U.S. FDA voted in favor of approving Vertex Pharmaceuticals’ (VRTX) new treatment for Cystic Fibrosis, Orkambi, on Tuesday afternoon. The … Continue Reading
Read NowInsights - Alexion Pharmaceuticals (ALXN) is buying fellow ultra orphan drug developer Synageva (GEVA) for $8.4 billion. Alexion will pay $115 in cash and 0.6581 Alexion shares … Continue Reading
Read Now
